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In this issue of Neuron, Viader et al. (2013) report on the production of toxic lipids by Schwann cells deficient
in mitochondrial respiration, which are capable of destroying neighboring axons. This may have implications
for understanding the neurobiology and treatment of mitochondrial neuropathies.Researchers interested in the neurobi-
ology of diseases have become increas-
ingly familiar with the notion that mito-
chondrial defects may be associated
not only with classical mitochondrial
diseases, such as MELAS (mitochondrial
encephalomyopathy, lactic acidosis, and
stroke-like episodes), but also with a
host of adult-onset neurodegenerative
disorders, including amyotrophic lateral
sclerosis and Parkinson’s disease
(Schon and Przedborski, 2011). Similarly,
non-cell-autonomous mechanisms have
been recognized as key factors under-
pinning many neurodegenerative disor-
ders (Garden and La Spada, 2012); here,
the idea is that nonneuronal cells, such
as glia, contribute to the demise of
neighboring neuronal cells. In this issue
of Neuron, Viader et al. (2013) report on
the successful collusion between mito-
chondrial defect and non-cell-autono-
mous mechanisms in a mouse model of
peripheral neuropathy.
The new study further characterized
a previously generated mouse model
that consists of a selective ablation of
the mitochondria transcription factor A
gene (Tfam) in Schwann cells (SCs)
(Viader et al., 2011). Because Tfam
controls the transcription, replication,
and stability of mitochondrial DNA
(mtDNA), its ablation in SCs led to the
depletion of mtDNA and a failure to
express the key components of the elec-
tron transport chain, causing a respiration
deficiency and an abnormalmitochondrialmorphology restricted to SCs (Viader
et al., 2011). Surprisingly, despite these
alterations, SC viability was not affected
but, instead, a progressive peripheral
neuropathy reminiscent of human dia-
betic neuropathies was observed. This
mouse neuropathy was characterized by
a preferential loss of small unmyelinated
C fibers, followed by that of large myelin-
ated axons and, ultimately, extensive
demyelination accompanied by behav-
ioral anomalies (i.e., distal weakness and
sensory deficits).
One of the first striking observations in
the current study of Viader et al. (2013) is
the absence of overt depletion of bioavail-
able ATP in sciatic nerve extracts (i.e.,
mixture of mutant SCs and wild-type
axons) in pre- or early-pathological
Tfam-SC conditional knockout (Tfam-
SCKO) mice, even though the authors
show that the respiratory chain function
is compromised in the mutant sciatic
nerves. This apparent paradox may find
a resolution in Viader et al. (2013)’s obser-
vation that lactate in the mutant nerve
extracts is 2-fold higher than controls,
most likely because mutant SCs have
upregulated their aerobic glycolysis.
That lactate, in turn, which is a favored
energy source for neurons (Wyss et al.,
2011), should have maintained the axonal
integrity. Relevant to this point is the
demonstration that in another mouse
model of respiratory chain deficiency in
SCs and their CNS counterparts, oligo-
dendrocytes, there is a demyelinatingNeuronneuropathy but, in striking contrast with
the study of Viader et al. (2013), without
axonal loss (Fu¨nfschilling et al., 2012).
Thus, a deficit of Tfam in SCs may be trig-
gering a non-cell-autonomous axonop-
athy by a mechanism other than energy
depletion. Viader et al. (2013) performed
an unbiased gene expression profile anal-
ysis of sciatic nerves from wild-type and
Tfam-SCKO mice, and their attention
was drawn to two particular sets of
differentially expressed genes. The first
one pertained to the integrated stress
response (ISR) (Harding et al., 2003),
such as Chop, Mthfd2, and Trib3.
Perhaps Viader et al. (2013) thought about
ISR as the potential culprit since they
knew that a demyelinating neuropathy
could result from ISR (Pennuto et al.,
2008). However, in contrast to the latter
study, here, the ISR was not linked to
either ER stress (e.g., phosphorylation of
PKR-like ER kinase or PERK) or the
unfolded protein response (e.g., upregu-
lation of BiP/Grp78 or activation of the
splicing factor IRE-1). Instead, Viader
et al. (2013) provided evidence that the
observed ISR is linked to heme-regulated
inhibitor kinase (HRI), which, in itself, is
a remarkable finding, as HRI had only
been shown to be activated by iron
deficiency in studies conducted primarily
in erythroid cells and never before con-
nected to a mitochondrial defect. Yet,
this exciting discovery remains, in the
present work, an open-ended story since
Viader et al. (2013) do not provide any77, March 6, 2013 ª2013 Elsevier Inc. 801
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the neuropathy of the Tfam-SCKO mice.
One can only hope that the role of HRI in
mitochondrial neuropathies will be the
subject of future studies. Similarly, we
may have to wait for further experiments
to better understand the nature of molec-
ular pathways linking Tfam deficiency,
HRI activation, and ISR response in
mediating the observed neuropathy.
The second set of differentially ex-
pressed genes, selected by Viader et al.
(2013), was associated with the control
of lipid metabolic pathways. For instance,
the expression levels of fatty acid synthe-
tase and HMG-CoA reductase (HMGCR)
were decreased (in the mutant samples),
while the phosphorylation of Acetyl-CoA
carboxylase (ACC), which is inhibitory,
was increased. Because ACC is known
to supply malonyl-CoA for the synthesis
of fatty acids, its phosphorylation is
predicted to reduce fatty acid syn-
thesis. Similarly, decreased expression
of HMGCR is expected to cause a
decrease in cholesterol synthesis. Alto-
gether, these features were strongly
suggestive of a defect in lipid synthesis
in nerve cells in response to SCmitochon-
drial dysfunction. To explore this idea
further, Viader et al. (2013) performed a
lipid analysis using state-of-the-art multi-
dimensional shotgun lipidomics. They
found in the mutant nerves a deficiency
in two subfamilies of glycosphingolipids,
cerebrosides and sulfatides, both of
which are primarily synthesized by SCs
and enriched in peripheral myelin (Chrast
et al., 2011). As Viader et al. (2013) remind
us, normal cerebroside and sulfatide
content in peripheral myelin is essential
for the maintenance of SC-axon contacts
and their absence disrupts paranodal
junctions, which separate voltage-gated
Na(+) and Shaker-type K(+) channels in
the node and juxtaparanode, respec-
tively. Consistent with earlier findings,
voltage-gated K(+) channel clusters
(Kv1.2) were disrupted in the juxtaparano-
dal axolema, probably causing the 40%
reduction in nerve conduction velocity
observed in mutant nerves and in agree-
ment with the ultrastructural anomalies
showing enlarged nodal gaps. Because
these lipid alterations occur before the
extensive demyelination and loss of
myelin proteins typically found in 4-
month-old and older animals, they are802 Neuron 77, March 6, 2013 ª2013 Elsevieprobably drivers of the neuropathy in this
animal model.
Not content to identify a rather simple
lipid-based ‘‘loss-of-function’’ mecha-
nism for the demyelination phenotype ob-
served in response to genetically induced
mitochondrial dysfunction, Viader et al.
(2013) were struck by the 25-fold in-
crease in acylcarnitine in mutant nerves,
with a phenomenal increase in long-chain
acylcarnitine species (several hundred
fold). Importantly, this accumulation of
lipids, which is arguably the most fasci-
nating finding reported in this study, is
intimately connected to mitochondrial
function because acylcarnitines are
metabolic intermediates in the transport
of fatty acyl groups across mitochondrial
membranes as the latter are destined for
b-oxidation, supplying a major source of
cellular energy (Kompare and Rizzo,
2008). Together with the gene expression
studies, the acylcarnitine phenotype
was consistent with a shift from lipid
synthesis toward lipid b-oxidation; yet,
an aberrant one as the lipid intermediates
were not efficiently oxidized, leading to
their accumulation. Corroborating this
idea, hydroxy-acylcarnitines were also
found to accumulate and the NAD+/
NADPH ratio was reduced. Importantly,
the buildup of acylcarnitines was obvious
in younger (i.e., 1-month-old) Tfam-SCKO
nerves, suggesting that it may be among
the earliest biochemical manifestations.
Furthermore, genetic disorders of fatty
acid b-oxidation, such as those caused
by mutations in long-chain hydroxyacyl-
CoA dehydrogenase or components of
the mitochondrial trifunctional protein
complex, are associated with enhanced
levels of acylcarnitines and juvenile forms
of peripheral neuropathies (Kompare and
Rizzo, 2008).
The next fundamental question was
therefore whether the aberrantly elevated
levels of acylcarnitine are toxic to the
neighboring axons, particularly in light of
previous studies showing that this amphi-
philic lipid, which is able to cross lipid
bilayers, can perturb the integrity and
permeability of cellular membranes (Ya-
mada et al., 2000). Remarkably, Viader
et al. (2013) showed evidence that
acylcarnitines not only are released into
the culture media by nerve explants, but
also are secreted in much larger
amounts by mutant SCs lacking Tfam,r Inc.particularly as long-chain species with
16 or 18 carbons (C16 or C18, respec-
tively), reaching micromolar concentra-
tions in the media within a couple of
days. Guided by these findings, Viader
et al. (2013) subsequently tested the
effect of palmitoyl-carnitine (i.e., C16) on
axonal Ca2+ homeostasis in dorsal root
ganglion (DRG) neurons loaded with the
Ca2+ dye Fluo-4. While acute applications
of this lipid caused a rise in intracellular
Ca2+ levels within minutes, subchronic
(i.e., for 4 days) applications led instead
to axonal anomalies, such as ‘‘blebbing,’’
denoting its neurotoxic properties. Over-
all, the study by Viader et al. (2013) makes
a strong case for mitochondrial dysfunc-
tion and its associated lipid metabolic
defects as early drivers of neuropathies
in the mouse.
This study by Viader et al. (2013) has
significant implications at multiple levels
and raises a number of important issues
as well. First, by genetically restricting
mitochondrial dysfunction to SCs via the
cell type-specific ablation of Tfam, the
study provides an elegant demonstration
that mitochondria can be driving patho-
logical processes relevant to neuropa-
thies of the PNS, both cell-autonomously
and non-cell-autonomously. Indeed, an
important consequence of the depletion
of mtDNA in SCs is a downregulation of
some aspects of lipid synthesis, which,
in turn, causes deficiencies in specific
lipid components of the myelin, such as
cerebrosides and sulfatides. These defi-
ciencies, which reflect a cell-autonomous
process, are likely to weaken the myelin
and may thus contribute to the progres-
sive demyelination observed in Tfam
mutant mice, exactly as shown by Fu¨nf-
schilling et al. (2012) in their mutant
study. In contrast, the identification of
acylcarnitines as candidate SC-derived
neurotoxic lipids is strongly suggestive
of non-cell-autonomous pathogenic
mechanisms. While this lipid subfamily
has already been linked to genetic
diseases involving disorders of lipid
b-oxidation and serves as a blood
biomarker for these conditions (Kompare
and Rizzo, 2008), this study not only
implies that acylcarnitines may be early
biomarkers for neuropathies with mito-
chondrial dysfunction as a causative
factor, but it also suggests that it may
underlie key aspects of pathogenicity
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thies. While micromolar concentrations
of long-chain acylcarnitine appear to be
‘‘axonotoxic’’ in cultured DRGs, a funda-
mental question is whether its levels
found in vivo at sites of intimate contacts
between SCs and axons can be suffi-
ciently high to exert toxicity. Further
work will be required to demonstrate
that this is the case, either by blocking
the synthesis of this lipid through genetic
or pharmacological means or by identi-
fying reagents, such as antibodies, that
can sequester it or diminish its levels.
However, the latter may be problematic
if acylcarnitines accumulate locally at
sites of SC-axon interactions and may
not be easily accessible by antibodies.
Additional key questions to answer
regarding these lipids are how they
promote toxicity. Typically, lipids exert
their actions either through direct effects
on lipid bilayers or via signaling mecha-
nisms involving protein effectors. In the
case of acylcarnitines, their soluble
amphiphilic nature may endow them
with surfactant properties, which could
destabilize cellular membranes and lead
to changes in permeability, perhapsaccounting for the increase in Ca2+ influx
found by Viader et al. (2013) in DRG
neurons treated with palmitoylcarnitine.
Alternatively, acylcarnitines may interact
with membrane proteins, including ion
channels, and perturb the permeability
of neuronal membranes through these
interactions. Whether axons are particu-
larly vulnerable to these lipids is another
important question, particularly in light of
a growing number of studies indicating
that degenerative mechanisms in axons
versus somatodendritic compartments
may be quite distinct. Finally, in light of
Viader et al. (2013)’s findings linking
mitochondrial dysfunction to the ISR
through the activation of protein kinase
HRI, a key question is what is the molec-
ular link between this kinase and machin-
eries controlling lipid synthesis and fatty
acid b-oxidation. In this respect, the fact
that ISR suppresses the synthesis of
both proteins and lipids is particularly
intriguing.REFERENCES
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Previous reports on dorsal and ventral hippocampal regulation of context learning versus anxiety have been
mixed. In this issue of Neuron, a new study by Kheirbek et al. (2013) using optogenetics demonstrates that
dentate gyrus granule cell activity in dorsal hippocampus encodes contextual fear learning while ventral
granule cell activity regulates anxiety behavior.The principal role of the hippocampus
in the formation of new memories has
been the primary focus of neuroscience
research for many years, but it has
become increasingly clear that this limbic
structure also plays a broader role in infor-
mation processing and behavior. Forexample, early neurobiological theories
considered the hippocampus an integral
part of the neural circuitry of emotional
experience, and neuroimaging studies
demonstrate that hippocampal dysfunc-
tion occurs more frequently in psychiatric
illnesses such as depression, bipolar, andanxiety disorders. However, the involve-
ment of the hippocampus has also been
viewed as ancillary, with no specific role
in emotion beyond general inhibitory
learning and the consolidation of memory
regardless of its emotional content (Le-
Doux, 2000).77, March 6, 2013 ª2013 Elsevier Inc. 803
